Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Investor Presentation (September 2025)
18 slides from Chimeric Therapeutics's investor presentation, Sep 9, 2025
Slide 1: Pioneers in Cell Therapy
For personal use only 25 20 CHI MERIC THE RAP EU TICS PIONEERS IN CELL THERAPY CHIMERIC ASX: CHM
Slide 2: Disclaimer
DISCLAIMER Certain statements contained in this presentation, including, without Given these uncertainties, undue reliance should not be placed on limitation, statements containing the words “believes,” “plans,” such forward-looking statements. The Company disclaims any “expects,” “anticipates,” and
Slide 3: Investment Highlights and Corporate Profile
INVESTMENT HIGHLIGHTS 4 4 Phase 1 clinical trials For personal use only CORPORATE PROFILE Multiple clinical updates CHI MERIC THE RAP EU TICS Stock code ASX:CHM Experienced leadership team in cell therapy clinical development Share price $0.003 CHM CDH17 52-week range $0.002-$0.017 the FIRST CDH17 C
Slide 4: Leadership Team
4 LEADERSHIP TEAM EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALISATION For personal use only CHI MERIC THE RAP EU TICS Dr Rebecca McQUALTER Dr Jason LITTEN Dr Stephanie ASTROW Chief Executive Officer Chief Medical Officer Chief Scientific Officer 50+ 50+ 5/7 EXPERIENCE EXPERTISE RESULTS Years of
Slide 5: CHM CDH17
For personal use only 25 20 CHI MERIC THE RAP EU TICS CHM CDH17 ASX: CHM
Slide 6: CDH17 Overview
6 CDH17 OVERVIEW Over a decade of development at the world- For personal use only renowned cell therapy centre, The University of Pennsylvania CHI MERIC THE RAP EU TICS Compelling pre-clinical efficacy in gastric, pancreatic and neuroendocrine Cancers Dr. Xianxin Hua, Dr. Carl June M.D. M.D., Ph.D.
Slide 7: Encouraging Pre-Clinical Results
7 ENCOURAGING PRE-CLINICAL RESULTS CDH17 CAR T induced complete eradication of tumours with no relapse in seven mouse models For personal use only NEUROENDOCRINE TUMOURS GASTRIC CANCER CHI MERIC THE RAP EU TICS PANCREATIC CANCER CHM CDH17 CAR-T 20 25 Source: Feng et al., Nature Cancer, 2022 C HI MER
Slide 8: CHM CDH17 CAR-T Phase 1/2 Recruiting
8 CHM CDH17 CAR-T PHASE 1 RECRUITING The first CDH17 CAR T cell therapy in clinical trials globally For personal use only PERSONALISED CAR-T: AUTOLOGOUS 4 prestigious sites recruiting: Sarah Cannon, UPenn, UChicago, Emory CHM CDH17 CHI MERIC THE RAP EU TICS CAR-T FDA IND clearance: Nov 23 Manufactur
Slide 9: Phase 1/2 Clinical Trial of CHM CDH17 Design
Phase 1/2 Clinical Trial of CHM CDH17 Design For personal use only CHI MERIC THE RAP EU TICS 20 NCT06055439 25 C HI MERI C THERAPEUTI CS.C OM
Slide 10: CHM CDH17 Progress as at September 2025
10 CHM CDH17 PROGRESS AS AT 8 SEPTEMBER 2025 For personal use only Dose Level Status Notes 1 50m Completed 4 patients treated CHI MERIC THE RAP EU TICS 1 patient remains on study 2 150m Recruitment ongoing 4 patients treated 3 450m Recruitment underway 2 patients awaiting dosing assignment Manufactu
Slide 11: Clinical Preliminary Results: Dose Level Completed
CLINICAL PRELIMINARY RESULTS 11 DOSE LEVEL 1 COMPLETED For personal use only 50m Cells Tumour Type Status Patient 1 CRC No follow up CHI MERIC THE RAP EU TICS Patient 2 NET Stable Disease until day 150 progression Grade 1 CRS Patient 3 CRC Stable Disease at day 270 Patient 4 CRC Progressive Disease
Slide 12: Clinical Preliminary Results: Dose Level Ongoing
CLINICAL PRELIMINARY RESULTS 12 DOSE LEVEL 2 Ongoing For personal use only 150m Cells Tumour Type Status Patient 5 CRC Stable Disease 90days CHI MERIC THE RAP EU TICS Tumour Shrinkage 12% Patient 6 NET Treated. Pending Day 28 scan Grade 3 CRS Patient 7 CRC Treated. Patient 8 CRC Treated. 20 25 CRC=
Slide 13: CHM CDH17 Progress: Recruitment Underway
CHM CDH17 PROGRESS 13 RECRUITMENT UNDERWAY For personal use only TBD Dose of Cells Tumour Type Status Patient 9 NET Manufactured. Dose yet to be assigned CHI MERIC THE RAP EU TICS Patient 10 NET Manufactured. Dose yet to be assigned TBD TBD 20 25 CRC= Colorectal Cancer (Bowel Cancer) NET= NeuroEndoc
Slide 14: Total Global Market Size
14 TOTAL GLOBAL MARKET SIZE For personal use only CHI MERIC THE RAP EU TICS $27.7Bin 2024 20 25 C HI MERI C THERAPEUTI CS.C OM
Slide 15: Summary + FY26 Catalysts
SUMMARY + FY26 CATALYSTS 8 patients treated For personal use only 10/10 manufacturing runs CHM CDH17 Anti-tumour activity observed CHI MERIC THE RAP EU TICS CHM 2101 No safety issues to date No off-target effects Complete Dose level 2 Commence Dose level 3 (if appropriate) Conclude Phase 1 Phase 2 r
Slide 16: Chimeric: Pioneers in Cell Therapy
For personal use only CHIMERIC CHI MERIC THE RAP EU TICS PIONEERS IN CELL THERAPY investors@chimerictherapeutics.com ASX: CHM 20 25
Slide 17: CHM: Broad Portfolio of Novel Cell Therapies
17 CHM: BROAD PORTFOLIO 3 novel cell therapies; 4 clinical trials For personal use only CHM CDH17 CHM CORE-NK CHM CLTX CHI MERIC THE RAP EU TICS CAR-T ‘OFF THE SHELF’ NK PHASE 1B PHASE 1B TRIAL OPEN TRIAL OPEN PHASE 1/2 TRIAL OPEN PHASE 1B TRIAL 4 sites active MD Anderson Case Western 1 site active
Slide 18: CHM CDH17 CAR T Target Competitors in Detail
CHM CDH17 CAR T TARGET COMPETITORS IN DETAIL For personal use only Preclinical Phase 1 CHM CHM CDH17 CHM CDH17 CDH17 CDH17 CAR T CDH17 CAR NK CDH17 CAR T Ospedale San Raffaele Chimeric Therapeutics Chimeric Therapeutics CHM 2101 CHI MERIC THE RAP EU TICS ARB011 ARB001 Cell CDH17 NK/T CDH17 CAR T The
Chimeric Therapeutics — Investor Presentation (September 2025) on 6ix